The thioredoxin system and cancer therapy: a review Fariba MohammadiArash SoltaniSeyed Isaac Hashemy Review Article 31 July 2019 Pages: 925 - 935
Prodrugs as drug delivery system in oncology J. DelahousseC. SkarbekA. Paci Review Article 07 August 2019 Pages: 937 - 958
Polymorphisms of genes encoding drug transporters or cytochrome P450 enzymes and association with clinical response in cancer patients: a systematic review Inthuorn KulmaKanyarat BoonprasertKesara Na-Bangchang Review Article 04 September 2019 Pages: 959 - 975
Exposure–response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients Silpa NuthalapatiSven StodtmannHao Xiong Original Article 29 August 2019 Pages: 977 - 986
Optimal dose of sunitinib for long-term treatment in Japanese patients with renal cell carcinoma Yuto YamadaYuta OhnoAkio Suzuki Original Article 03 September 2019 Pages: 987 - 992
Population pharmacokinetics of siltuximab: impact of disease state Mina NikanjamJin YangEdmund V. Capparelli Original Article 03 September 2019 Pages: 993 - 1001
Population pharmacokinetics and exposure–overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer Ivelina GueorguievaJosep TaberneroKarim A. Benhadji Original Article 03 September 2019 Pages: 1003 - 1015
Evaluation of the potential for QTc prolongation with avelumab Yulia VugmeysterGülseren GüzelHaiqing Dai Original Article Open access 03 September 2019 Pages: 1017 - 1026
Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors and those with hepatocellular carcinoma K. YamazakiT. DoiA. Ohtsu Original Article 03 September 2019 Pages: 1027 - 1037
Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab Baoquan LiuFei SuJianguo Zhang Original Article 04 September 2019 Pages: 1039 - 1049
Real-world data on initial treatment strategies for older adult patients with endometrial cancer in Japan Mayu YunokawaShinsuke SasadaKenji Tamura Original Article 04 September 2019 Pages: 1051 - 1058
Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer Midori ShimadaHiroyuki YamaguchiHiroshi Mukae Original Article 05 September 2019 Pages: 1059 - 1064
A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients Tetsuo TaniKatsuhiko NaokiKenzo Soejima Original Article 06 September 2019 Pages: 1065 - 1071
Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice Jim H. HughesRichard N. UptonDavid J. R. Foster Original Article 06 September 2019 Pages: 1073 - 1087
Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer Gerardo RosatiRaffaele AddeoSalvatore Bianco Original Article 06 September 2019 Pages: 1089 - 1096
Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases Kazuyo ShimadaShiori HasegawaMitsuhiro Nakamura Original Article 09 September 2019 Pages: 1097 - 1105
Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study Takumi SakuradaSanako BandoKeisuke Ishizawa Original Article 09 September 2019 Pages: 1107 - 1114
A phase I study evaluating combined nimotuzumab and neoadjuvant chemoradiotherapy followed by surgery in locally advanced esophageal cancer Saichun QiYa MaoMingjun Jiang Original Article 09 September 2019 Pages: 1115 - 1123
Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects Kiana KeyvanjahBlaire CookeAlvin Wong Original Article 11 September 2019 Pages: 1125 - 1132
Downregulation of SRSF3 by antisense oligonucleotides sensitizes oral squamous cell carcinoma and breast cancer cells to paclitaxel treatment Yanan SunLingyan YanRong Jia Original Article 12 September 2019 Pages: 1133 - 1143
A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies Filipa LynceHongkun WangMichael J. Pishvaian Clinical Trial Report 19 September 2019 Pages: 1145 - 1151
